Page 5 - Challenge Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Vaxart Announces Additional Preclinical COVID-19 Oral Vaccine Data and Publication January 26, 2021 08:30 ET | Source: Vaxart, Inc. Vaxart, Inc. South San Francisco, California, UNITED STATES New pre-clinical histology data show that Vaxart’s oral vaccine protected against lung inflammation in hamster models An article published in Nature Medicine reports data from a collaboration with Stanford University researchers on in vitro activity of Vaxart’s COVID-19 vaccine Data from Vaxart’s Phase I COVID-19 trial expected to be released next week S...

Published: Jan 26, 2021 New pre-clinical histology data show that Vaxart’s oral vaccine protected against lung inflammation in hamster models An article published in Nature Medicine reports data from a collaboration with Stanford University researchers on in vitro activity of Vaxart’s COVID-19 vaccine Data from Vaxart’s Phase I COVID-19 trial expected to be released next week SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Vaxart Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by inject...

Share: BARDA-sponsored study shows second-generation hAd5 vaccine candidate in both subcutaneous and room temperature oral formulations inhibits SARS-CoV-2 virus replication to undetectable levels and clears infection within days in 100% of vaccinated non-human primates The second-generation human adenovirus vector hAd5, which delivers both outer spike (S) and inner nucleocapsid (N) antigens, induced T cells and antibodies leading to reduction of SARS-CoV-2 viruses in both lungs and nasal passages within seven days The hAd5-COVID-19 oral capsule vaccine candidate was effective at room tempera...